Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant GM-CSF + Thalidomide in High-Risk Prostate Cancer
NCT00400517Phase 2Completed
- Sponsor
- Cleveland Clinic
- Start
- Mar 2003
- Primary completion
- Jun 2008
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sargramostim and thalidomide in prostate cancer (PCa), sponsored by Cleveland Clinic. Primary endpoints: Proportion of Patients P0 at Surgery at 8 weeks, Proportion of Patients With Negative Surgical Margins at 8 weeks and 2 more. Started Mar 2003; status: completed.
02
Drugs
sargramostimthalidomide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00400517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00400517.